US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Nuvalent, Inc. - Class A Common Stock (NQ:NUVL)

123.96 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvalent, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether ATAI, CCRN, NUVL are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
From Brodsky & Smith LLC
Via GlobeNewswire
Nuvalent Inc-A (NASDAQ:NUVL) Stock Edges Higher After Q1 2026 Earnings Miss as Investors Focus on Pipeline Milestones ↗
Via Chartmill
Topics Earnings
News headline image
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether DAN, ESI, NUVL, BOLD are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Element Solutions Inc. (NYSE – ESI), Boundless Bio Inc. (Nasdaq – BOLD), Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders
From Ademi LLP
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether LCII, NUVL, DAN, TMHC are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC),
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Arcosa, Inc. (NYSE – ACA), Fathom Holdings Inc. (Nasdaq – FTHM), Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether ALOT, NUVL, BGMS are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether DAN, NUVL, SUNE, TMHC are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 06/08 - 06/12 ↗
Stocks rallied on optimism surrounding a potential U.S.-Iran peace deal and SpaceX's historic IPO debut, reinforcing investor confidence and market momentum 
Via MarketBeat
Topics Economy Initial Public Offering
News headline image
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗
GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff. 
Via MarketBeat
Topics Intellectual Property
News headline image
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
From Kahn Swick & Foti
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Tuesday's session: top gainers and losers ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), SUNation Energy, Inc. (Nasdaq – SUNE), Organon & Co. (NYSE – OGN), Taylor Morrison Home Corporation (NYSE – TMHC)
From Brodsky & Smith LLC
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Which stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
NUVL Stock Alert: Halper Sadeh LLC is Investigating Whether Nuvalent, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
Get insights into the top gainers and losers of Tuesday's pre-market session. ↗
Via Chartmill
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer. 
Via The Motley Fool
News headline image
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology. 
Via The Motley Fool
News headline image
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗
Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 Next >